RX
RXRX.US Recursion Pharmaceuticals Inc
- Market cap
- USD 1.70B
- P/E
- -
- P/B
- 2.00x
- ROE
- -54.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is RXRX.US undervalued?
Graham numberThe Graham number of Recursion Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Recursion Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Recursion Pharmaceuticals Inc yet.
Recursion Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced…
Full company profileRecursion Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Recursion Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 1.71M | 3.41M | 10.0M | 39.7M | 43.9M | 58.8M | 74.7M | 43.6M |
| Gross Profit | -44.1M | 3.41M | 10.0M | -8.59M | 1.29M | 13.6M | -46.3M | -1.78M |
| Operating Income | -62.4M | -84.6M | -183M | -246M | -350M | -479M | -648M | -516M |
| EBITDA | -59.4M | -81.7M | -174M | -234M | -308M | -427M | -559M | -423M |
| Net Income | -62.5M | -87.0M | -178M | -239M | -328M | -464M | -645M | -490M |
| EPS | -0.38 | -0.52 | -1.05 | -1.36 | -1.58 | -1.69 | -1.44 | -0.90 |
| Balance Sheet | ||||||||
| Total Assets | 101M | 299M | 610M | 701M | 654M | 1.45B | 1.47B | 1.22B |
| Total Liabilities | 226M | 505M | 67.4M | 215M | 190M | 414M | 343M | 316M |
| Shareholders' Equity | -124M | -206M | 543M | 486M | 463M | 1.03B | 1.13B | 906M |
| Cash & Short-term Investments | 69.9M | 262M | 517M | 550M | 392M | 594M | 743M | 550M |
| Total Debt | 16.2M | 15.7M | 11.5M | 51.0M | 50.7M | 108M | 78.0M | 74.7M |
| Cash Flow | ||||||||
| Operating Cash Flow | -57.0M | -45.4M | -159M | -83.5M | -288M | -359M | -372M | -353M |
| Capital Expenditure | 3.91M | 6.74M | 39.8M | 37.4M | 12.0M | 13.7M | 6.47M | 3.61M |
| Free Cash Flow | -61.0M | -52.1M | -198M | -121M | -300M | -373M | -378M | -356M |
| Ratios | ||||||||
| ROE | - | - | -32.8% | -49.3% | -70.8% | -44.8% | -57.0% | -54.1% |
| ROA | -61.6% | -29.1% | -29.2% | -34.1% | -50.2% | -32.0% | -43.7% | -40.1% |
| Net Profit Margin | -3,654.3% | -2,549.3% | -1,780.7% | -603.4% | -747.7% | -788.0% | -863.4% | -1,124.2% |
| Debt to Equity | - | - | 0.02x | 0.10x | 0.11x | 0.10x | 0.07x | 0.08x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Recursion Pharmaceuticals Inc dividends
Recursion Pharmaceuticals Inc has not paid dividends in the last 7 fiscal years.
Who owns Recursion Pharmaceuticals Inc
- Insiders 1.77%
- Institutions 66.16%
- Public & others 32.07%
- Shares outstanding 623M
- Free float 607M
Top funds holding RXRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| ARK Innovation ETF | 24.1M | 3.87% | -3.15% | Oct 2026 |
| Scottish Mortgage Ord | 18.2M | 2.92% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 17.8M | 2.86% | +2.69% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 16.0M | 2.57% | +0.63% | Sep 2026 |
| ARK Genomic Revolution ETF | 15.9M | 2.56% | +0.58% | Oct 2026 |
| iShares Russell 2000 ETF | 13.0M | 2.08% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 11.5M | 1.84% | -0.08% | Sep 2026 |
| WisdomTree Art Intelligence ETF USD Acc | 8.14M | 1.31% | 0.00% | Oct 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 6.27M | 1.01% | -4.59% | Sep 2026 |
| Vanguard Strategic Equity Inv | 6.25M | 1.00% | +60.82% | Sep 2026 |
| Fidelity Small Cap Index | 5.63M | 0.90% | +0.68% | Aug 2026 |
| iShares Russell 2000 Value ETF | 4.36M | 0.70% | 0.00% | Oct 2026 |
| iShares Biotechnology ETF | 4.18M | 0.67% | +12.28% | Oct 2026 |
| FT Nasdaq Artfcl Intllgnc and Rbtc ETF | 3.51M | 0.56% | 0.00% | Oct 2026 |
| Schwab US Small-Cap ETF™ | 3.16M | 0.51% | +0.24% | Oct 2026 |
| Vanguard Strategic Small-Cap Equity Inv | 3.11M | 0.50% | +115.65% | Sep 2026 |
| Amova ARK Disruptive Innovation A USD | 2.98M | 0.48% | -4.20% | Sep 2026 |
| Vanguard Russell 2000 ETF | 2.97M | 0.48% | +0.97% | Sep 2026 |
| Fidelity Extended Market Index | 2.54M | 0.41% | -3.85% | Sep 2026 |
| Vanguard Explorer Inv | 2.34M | 0.38% | 0.00% | Sep 2026 |
Top institutions holding RXRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 50.3M | 8.07% | +16.47% | Jun 2026 |
| ARK Investment Management LLC | 41.3M | 6.63% | +2.80% | Jun 2026 |
| State Street Corp | 34.7M | 5.57% | +21.82% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 31.1M | 4.99% | +36.79% | Jun 2026 |
| Vanguard Capital Management, LLC | 22.8M | 3.65% | +2.34% | Jun 2026 |
| Baillie Gifford & Co Limited. | 18.2M | 2.92% | -22.62% | Sep 2026 |
| Geode Capital Management, LLC | 13.8M | 2.22% | +12.58% | Jun 2026 |
| SoftBank Group Corp | 13.6M | 2.19% | 0.00% | Jun 2026 |
| UBS Group AG | 8.95M | 1.44% | +75.39% | Jun 2026 |
| MIC Capital Management UK LLP | 8.26M | 1.32% | -14.40% | Sep 2026 |
| NORGES BANK | 6.83M | 1.10% | +19.07% | Jun 2026 |
| Data Collective IV GP, LLC | 5.94M | 0.95% | 0.00% | Jun 2026 |
| Amova Asset Management Americas, Inc | 5.51M | 0.88% | +1.71% | Jun 2026 |
| Sumitomo Mitsui Trust Group Inc | 5.51M | 0.88% | +1.71% | Jun 2026 |
| Northern Trust Corp | 4.76M | 0.76% | +19.90% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 4.71M | 0.76% | +63.88% | Jun 2026 |
| Charles Schwab Investment Management Inc | 4.14M | 0.66% | +8.65% | Jun 2026 |
| DCVC Opportunity Fund II GP, LLC | 3.95M | 0.63% | 0.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 3.92M | 0.63% | -35.41% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 3.47M | 0.56% | -1.26% | Jun 2026 |
Recursion Pharmaceuticals Inc company profile
- Company name
- Recursion Pharmaceuticals Inc
- Ticker
- RXRX.US
- Exchange
- USA Stocks
- Listed since
- Apr 16, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 600
- Fiscal year end
- December
- Address
- 41 South Rio Grande Street, Salt Lake City, UT, United States, 84101
- Phone
- 385 269 0203
- Website
- recursion.com
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Recursion Pharmaceuticals Inc management
10- Dr. Najat Khan Ph.D.CEO, President & Director · born 1984
- Mr. Ben R. TaylorCFO & President of Recursion UK · born 1977
- Mr. Benjamin Mabey M.S.Chief Technology Officer · born 1983
- Dr. David Hallett Ph.D.Chief Scientific Officer · born 1969
- Mr. Nathan Hatfield J.D., M.B.A.Chief Legal Officer & Corporate Secretary
- Mr. Ryan KellyChief Communications Officer
- Ms. Erica FoxChief People and Impact Officer
- Mr. Matthew Kinn M.B.A.Chief Business Officer
- Mr. Sid JainSenior Vice President of Clinical Development & Data Science
- Dr. Vicki L. Goodman M.D.Chief Medical Officer · born 1971